Oncology
xInflammation
xThe content in this page is intended only for residents of the United States. The medicines displayed herein may have different labeling in different countries. Please note that not all the medicines are available in all countries.
Overview
From long-acting HIV prevention and treatment to promising targets in cancer therapy, we’re discovering, evaluating and advancing investigational compounds that have the potential to transform care for life-threatening diseases. We have a strong and diverse pipeline and are on track to achieve our ambition, set in 2019, of delivering 10+ transformative therapies by 2030. Through pioneering science and innovative partnerships, we’ll continue to expand our research and development programs to take on pressing unmet needs in virology, oncology and inflammation.
Gilead Pipeline at a Glance
Updated: April 24, 2025, data as of end of Q1
Clinical stage programs**
Opt-in Programs
Phase 1
Phase 2
Phase 3
Therapeutic Areas
Trial Phase
xUnderstanding Pipeline Terms
- Phase 1
- Phase 2
- Phase 3
- Opt-in Programs
Phase 1
Phase 1
Phase 1 clinical trials test an investigational therapy in humans for the first time, with a focus on safety. Participants can be healthy or have been diagnosed with a specific condition.
Phase 2
Phase 2
Phase 2 clinical trials study efficacy while also collecting data about safety. Participants have been diagnosed with a specific condition that is being studied.
Phase 3
Phase 3
Phase 3 clinical trials involve a larger group of patients and study the efficacy of the investigational therapy in comparison to other approved or experimental therapies. The study is designed to gather information for the investigational therapy to be used in a specific population.
Opt-in Programs
Opt-in Programs
At Gilead, an opt-in program is an existing program of a Gilead or Kite partner to which Gilead or Kite has an “opt-in” right to participate in the future development and/or commercialization of the program. The specific terms of the opt-in right and future participation are governed by collaboration, option or similar agreements.
Clinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We currently offer more than 25 therapies in the U.S. and are rapidly growing our portfolio through research and development, as well as collaborations.
Research
We aim to continuously bring new therapies into clinical development and are propelled by our passion to save the lives of people around the world.